Tag: nasdaq:psti

December 2, 2019

Top 10 Stem Cell Companies On The NASDAQ

The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021....
November 28, 2018

Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will...
October 16, 2018

U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

Pluristem Therapeutics (Nasdaq:PSTI;TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial a privately-held third-party sponsor...
September 25, 2018

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the U.S. Food...
August 8, 2018

Pluristem Initiates Two Pivotal Phase III Studies in Israel

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Israel’s Ministry of Health has cleared...
July 9, 2018

Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a strategic...